A legal battle is unfolding over the safety and marketing of the WaveWriter Alpha, a spinal cord stimulator designed to alleviate chronic pain, after a patient alleges the device not only failed to perform but caused novel, debilitating injuries that required surgical removal.
The lawsuit, filed by Tone Silas, describes a harrowing trajectory from hope to harm. After being implanted with the Boston Scientific WaveWriter Alpha system in January 2024, Silas reports that the initial relief he experienced was short-lived. By April 2024, the patient began suffering from sharp, shooting pains in his abdomen and hip, while the device’s ability to manage his original chronic pain steadily eroded. The system was eventually surgically removed approximately one year after the initial procedure.
At the heart of the WaveWriter Alpha lawsuit are claims that Boston Scientific prioritized sales over patient safety by allowing unlicensed representatives to perform critical medical functions. The complaint alleges that these representatives—who lacked medical training—were the primary individuals responsible for programming the device and selecting the electrical waveforms used to treat the patient, tasks that the lawsuit argues constitute the practice of medicine without a license.
As a physician, I recognize that the “programming” of a spinal cord stimulator is not merely a technical adjustment; it is a clinical intervention. These devices deliver electrical pulses to the dorsal columns of the spinal cord to mask pain signals. The precise placement of the leads and the specific configuration of the waveforms are what determine whether a patient finds relief or experiences painful “shocks” or ineffective therapy. When these adjustments are made based on a patient’s real-time feedback, it is a diagnostic and therapeutic process that typically requires medical licensure.
Allegations of Deception and Defective Design
The legal complaint outlines a series of failures regarding how the WaveWriter Alpha was presented to the patient. According to the filing, Silas underwent a trial period with a temporary unit intended to mirror the functionality of the permanent implant. However, the lawsuit claims the permanent device was significantly different from the trial unit, contrary to what Boston Scientific sales representatives had led the patient to believe.
the lawsuit alleges that the WaveWriter Alpha was approved without independent clinical testing. Instead, the plaintiff indicates that the company relied on data from older, legacy devices, despite implementing radical changes to how the new system functions.
“During the time in which the SCS system was implanted in Plaintiff, Boston Scientific representatives, believed to be unlicensed in the State of Louisiana, or elsewhere for that matter, actively participated in implanting the WaveWriter Alpha, and programming and waveform selection post-operatively. These actions involved real-time interpretation of patient responses and materially influenced the configuration and function of the implanted system. These actions were essentially medical treatment and had a significant impact on the way the SCS system affected Plaintiff’s body.”
The legal claims brought by Silas are extensive, encompassing manufacturing defects, failure to warn, negligence, and breach of warranty. The suit also alleges fraudulent misrepresentation and concealment, alongside violations of the Louisiana Unfair Trade Practices and Consumer Protection Law. Notably, the action includes a claim against the U.S. Food and Drug Administration (FDA) for alleged violations of the Administrative Procedure Act.
A Broader Crisis in Spinal Cord Stimulation
The issues facing Boston Scientific are not isolated. The medical device industry is currently seeing a surge in litigation regarding spinal cord stimulators (SCS). Similar lawsuits have been filed nationwide against other major manufacturers, including Medtronic and Abbott Laboratories, often citing lead migration, wire fractures, and inadequate warnings about potential complications.
This systemic issue has led to a push for the centralization of these legal battles. In March, a group of plaintiffs seeking damages from both Boston Scientific and Abbott requested that the Judicial Panel on Multidistrict Litigation (JPML) consolidate their federal cases into a single Multidistrict Litigation (MDL) in the Northern District of Illinois. An MDL allows one judge to handle all pretrial proceedings and discovery, which can streamline the process when hundreds of patients report similar injuries from the same type of device.
However, the manufacturers are fighting this consolidation. Boston Scientific and Abbott have urged the JPML to reject the motion, arguing that the products involved are too different to share a “common defect.” They further contend that many of the cases are already too far along in the legal process for consolidation to be efficient. Boston Scientific has also suggested that many of these claims may be preempted by federal law, a common defense in medical device litigation where companies argue that FDA approval shields them from certain state-level product liability claims.
Summary of Legal Claims and Status
| Key Issue | Plaintiff Allegations | Manufacturer Defense |
|---|---|---|
| Device Programming | Unlicensed reps performed medical treatment | Technical support is not medical practice |
| Clinical Testing | Relied on old data; lacked independent trials | FDA approval process followed |
| Case Management | Request for MDL consolidation in Illinois | Lack of common defect; federal preemption |
| Patient Outcomes | New pain, device failure, surgical removal | Varying patient responses; not a systemic defect |
What So for Patients
For those living with chronic pain, the prospect of a spinal cord stimulator is often a last resort. When these devices fail or cause further injury, the physical and psychological toll is significant. The removal of an implanted system is an invasive surgery that carries its own risks, including infection and scarring of the neural tissue.
Patients who have experienced adverse outcomes—such as unexpected sharp pain, loss of device efficacy, or the require for premature explantation—are currently being evaluated by legal teams to determine if their injuries stem from manufacturing defects or a failure to warn about known risks.
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Patients should consult with a licensed healthcare provider regarding medical device concerns and a qualified attorney for legal guidance.
The next critical juncture in this legal saga will occur this summer, when the JPML is expected to schedule oral arguments regarding the consolidation of the federal cases. The decision will determine whether these claims move forward as isolated battles or as a unified front against the manufacturers.
We invite readers to share their experiences with medical device implants in the comments below or reach out to our editorial team.
